Bank of New York Mellon Corp Buys 1,553 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Bank of New York Mellon Corp grew its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,569 shares of the company’s stock after purchasing an additional 1,553 shares during the period. Bank of New York Mellon Corp owned about 0.09% of CRISPR Therapeutics worth $3,014,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. First Horizon Advisors Inc. increased its holdings in shares of CRISPR Therapeutics by 33.4% in the 4th quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company’s stock worth $80,000 after buying an additional 511 shares during the last quarter. Ipswich Investment Management Co. Inc. lifted its stake in shares of CRISPR Therapeutics by 3.1% in the 4th quarter. Ipswich Investment Management Co. Inc. now owns 25,288 shares of the company’s stock valued at $995,000 after purchasing an additional 750 shares during the period. Private Advisor Group LLC boosted its stake in CRISPR Therapeutics by 18.5% during the fourth quarter. Private Advisor Group LLC now owns 85,036 shares of the company’s stock worth $3,347,000 after acquiring an additional 13,289 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in shares of CRISPR Therapeutics by 10.8% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 44,692 shares of the company’s stock valued at $1,759,000 after acquiring an additional 4,351 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in shares of CRISPR Therapeutics by 2,117.4% during the fourth quarter. Allworth Financial LP now owns 15,078 shares of the company’s stock valued at $593,000 after purchasing an additional 14,398 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $41.17 on Friday. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $75.91. The firm has a 50 day simple moving average of $43.06 and a 200-day simple moving average of $45.41. The firm has a market cap of $3.53 billion, a price-to-earnings ratio of -9.42 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CRSP. The Goldman Sachs Group reduced their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research note on Wednesday, February 12th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Finally, Barclays increased their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.